NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 101
(Total Views: 56)
Posted On: 09/30/2024 4:49:39 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed three new patents. According to the announcement, the patents cover combination therapies involving its lead compound, buntanetap, combined with Trulicity(R)(dulaglutide) and Viagra(R)(sildenafil), as well as a combination of all three. The company noted buntanetap inhibits the production of neurotoxic proteins and has been shown to improve cognition in early AD patients and halt cognitive decline in PD patients.
“Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. “The combination of buntanetap with Trulicity and Viagra not only has the potential to restore cognition to healthy levels, but also to improve it beyond normal, offering new hope in the fight against dementia. Since buntanetap has completed phase 3 studies as a standalone treatment, and both Trulicity and Viagra are FDA-approved, these combinations are well-positioned for phase 3 human trials.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed three new patents. According to the announcement, the patents cover combination therapies involving its lead compound, buntanetap, combined with Trulicity(R)(dulaglutide) and Viagra(R)(sildenafil), as well as a combination of all three. The company noted buntanetap inhibits the production of neurotoxic proteins and has been shown to improve cognition in early AD patients and halt cognitive decline in PD patients.
“Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. “The combination of buntanetap with Trulicity and Viagra not only has the potential to restore cognition to healthy levels, but also to improve it beyond normal, offering new hope in the fight against dementia. Since buntanetap has completed phase 3 studies as a standalone treatment, and both Trulicity and Viagra are FDA-approved, these combinations are well-positioned for phase 3 human trials.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Anv Sec Group Inc. (ANVS) Stock Research Links
Scroll down for more posts ▼